The FDA-cleared CancerDetect assay is claimed to be the first test in the world to detect oral cancer and throat cancer with 95% specificity and 90% sensitivity rates
US-based biotechnology company Viome Life Sciences has introduced its new CancerDetect test for oral and throat cancer, the first in a series of diagnostic tests in development.
The FDA-cleared CancerDetect assay is claimed to be the first test in the world to detect oral cancer and throat cancer with 95% specificity and 90% sensitivity rates.
For those who are at higher risk of acquiring certain diseases, CancerDetect fills a gap in the market by providing advanced, early detection when it is most manageable, said the company.
Viome believes that the launch of the CancerDetect indicates a bright future for saliva-based, early cancer detection testing with the company’s advanced mRNA technology and AI-powered solution.
CancerDetect gives remarkable accuracy to early cancer detection and prevention as the detection is very challenging, said Viome.
The test has been designed to identify early-stage cancer, which, when verified by a biopsy, leads to better treatment outcomes.
Viome Life Sciences founder and CEO Naveen Jain said: “Despite all the innovations across the health landscape, oral and throat cancer has remained life-threatening diseases with few options for early detection.
“As an industry leader on a mission to identify and address the roots of chronic disease, we have been working for years to bring to market clinically-backed diagnostics solutions for cancer detection and other life-threatening and debilitating diseases.”
Jain added: “With the launch of CancerDetect for Oral and Throat Cancer, we have achieved this goal and plan to follow this in rapid succession with detection tools for additional life-threatening chronic diseases and cancers.”
The test is the latest addition to Viome’s line of clinically validated Intelligence health tests, which also includes the most advanced at-home microbiome test currently on the market, the Full Body Intelligence Test.
The company is currently focusing on improving its tests for the range of GI illnesses, including malignancies, following the success of CancerDetect for oral and throat cancer.